-
公开(公告)号：US20190023763A1
公开(公告)日：2019-01-24
申请号：US16154457
申请日：2018-10-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , C12N15/115 , A61K39/00 , G01N33/574 , C12Q1/6881 , A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783 , C07K14/47 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
462.发明申请公开(公告)号：US20190016779A1
公开(公告)日：2019-01-17
申请号：US16132293
申请日：2018-09-14
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , C12Q1/6886 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C12N5/0783 , G01N33/574 , C07K16/28 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
463.发明申请公开(公告)号：US20190015492A1
公开(公告)日：2019-01-17
申请号：US16116323
申请日：2018-08-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C12N15/115 , C07K14/72 , G01N33/574 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/725 , C07K14/71 , C12N9/12 , C12N9/02 , C12N5/0783 , G06F19/20 , C12Q1/6886 , C07K16/40 , C07K16/38 , C07K16/30 , C07K16/28 , C07K16/18 , C07K14/81 , A61K38/00 , A61K35/17
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/705 , C07K14/7051 , C07K14/71 , C07K14/721 , C07K14/8135 , C07K16/18 , C07K16/28 , C07K16/2863 , C07K16/2869 , C07K16/30 , C07K16/38 , C07K16/40 , C07K2317/34 , C07K2317/76 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/0091 , C12N9/1264 , C12N15/115 , C12N2310/16 , C12N2502/11 , C12Q1/6886 , C12Q2600/156 , C12Y116/01 , C12Y207/07031 , G01N33/57484 , G01N2333/47 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20190010190A1
公开(公告)日：2019-01-10
申请号：US16136008
申请日：2018-09-19
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61K35/17 , C07K14/74 , A61K39/00 , C12N5/0783 , G01N33/574 , A61M5/00 , C07K7/08 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
465.发明申请公开(公告)号：US20180353586A1
公开(公告)日：2018-12-13
申请号：US16109451
申请日：2018-08-22
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K14/74 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C12N15/115 , C12N5/0783 , C07K16/30 , C07K16/28 , A61K35/17 , A61K38/00
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K2317/34 , C12N5/0636 , C12N15/115 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
466.发明申请公开(公告)号：US20180344827A1
公开(公告)日：2018-12-06
申请号：US16100498
申请日：2018-08-10
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MÜLLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC: A61K39/00 , G01N33/574 , C12Q1/6886 , C07K14/47 , C12N15/115 , C07K16/30 , G01N33/68 , C12N5/0783 , C07K14/725 , A61K38/00
CPC classification number: A61K39/0011 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C07K2319/00 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N33/5748 , G01N33/6848 , G01N2570/00 , G01N2800/52
Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
-
467.发明申请公开(公告)号：US20180256693A1
公开(公告)日：2018-09-13
申请号：US15978700
申请日：2018-05-14
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
IPC: A61K39/00 , C07K16/30 , C12N5/0783 , C12N15/115 , A61K35/17 , C07K16/28 , G06F19/20 , C07K14/74 , C07K16/18 , C07K14/47 , A61K35/12 , C07K14/705
CPC classification number: A61K39/0011 , A61K35/17 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G06F19/20
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20180251519A1
公开(公告)日：2018-09-06
申请号：US15984681
申请日：2018-05-21
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , G01N33/569 , A61K51/10 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , A61K39/00
CPC classification number: C07K14/70539 , A61K39/0011 , A61K51/1027 , A61K51/1057 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/70503 , C07K16/2833 , C07K16/303 , C07K2317/72 , C07K2317/73 , C07K2319/00 , C07K2319/30 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12P21/02 , C12Q1/6881 , C12Q2600/156 , C12Q2600/158 , G01N33/56977 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
469.发明申请公开(公告)号：US20180251517A1
公开(公告)日：2018-09-06
申请号：US15970194
申请日：2018-05-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/08 , C07K16/30 , A61K39/00 , A61K45/06 , C12N5/0783 , C12N9/64 , G01N33/50 , G01N33/566 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , A61K38/06 , G01N33/569 , C12Q1/6886 , A61K38/17
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
470.发明申请公开(公告)号：US20180208641A1
公开(公告)日：2018-07-26
申请号：US15919984
申请日：2018-03-13
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K39/00 , G01N33/566 , A61K38/08 , C07K7/02 , C07K7/06 , C07K14/47 , C07K16/30 , C12Q1/6886 , C07K14/725 , A61K45/06 , C07K16/28 , G01N33/569 , G01N33/50 , A61K38/17 , C07K14/00 , C12N5/0783 , C12N9/64 , C07K16/18
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
623
records
(took 0.075 seconds)
